United Therapeutics Reports ‘Solid’ Fourth Quarter As Inhaled Remodulin Gains Fans
This article was originally published in The Pink Sheet Daily
Executive Summary
Look for NDA filing for Viveta in June, approval in first half of 2009, analyst tells “The Pink Sheet” DAILY.